Resident: Attending: Expert: User: Stage 1: History & Presentation (Timestamp: 6 Weeks Prior to Admission)
An 80-year-old female retired cworker (residing in Delhi NCR, 50-pack-year smoking history, past history of HTN and dyslipidemia) presents with a 6-week history of subacute progressive fatigue, lightheadedness, nausea, low-grade fevers, early satiety, dysphagia, and unintentional 6 kg weight loss.
HPI:
- 6 Weeks Ago: Transient episode of nausea, vomiting, diarrhea, and fever (38.9°C) resolving spontaneously, followed by progressive exertional fatigue and solid-food dysphagia.
- 2 Weeks Prior: Evaluated at a regional hospital for severe lightheadedness and weakness. Found to have profound pancytopenia (Hb 8.2 g/dL, WBC 2.7 x 10³/µL, Platelets 57,000/µL) and schistocytes on peripheral blood smear.
- Presumed TTP: Given peripheral schistocytes and cytopenias, TTP was suspected. A tunneled internal jugular catheter was placed, and therapeutic Plasma Exchange (PLEX) was initiated. UGI endoscopy confirmed esophageal candidiasis, treated with oral Fluconazole.
Hello, Chief Resident here.
Key Findings: 80-year-old female (50 pack-year smoker) presenting with 6 weeks of constitutional symptoms, weight loss, solid-food dysphagia, esophageal candidiasis, and pancytopenia with microangiopathic hemolytic anemia (schistocytes), currently empirically treated for TTP.
Differential Diagnoses:
1. Disseminated Gastric / Solid Malignancy with Marrow Infiltration & Secondary MAHA (35%): Dysphagia, early satiety, weight loss, and smoking history strongly suggest a primary GI or metastatic neoplasm driving secondary thrombotic microangiopathy.
2. Primary Hematologic Malignancy (MDS / AML / Lymphoma) (30%): Profound pancytopenia, advanced age, and opportunistic infection point toward primary bone marrow failure or infiltration.
3. Disseminated Infection (e.g., Tuberculosis, Histoplasmosis, Leishmaniasis) (20%): Endemic location (India), fevers, cytopenias, and immunosuppression make chronic infection high priority.
4. Primary TTP / TMA (15%): Schistocytes and cytopenias fit, but prominent B-symptoms and mucosal candidiasis suggest an underlying primary trigger.
Prioritized Next Diagnostic Tests:
1. Bone Marrow Aspirate & Biopsy: Flow cytometry, cytogenetics, and histopathology/cultures (AFB, fungal).
2. CT Chest, Abdomen, and Pelvis with IV contrast: Evaluate for occult malignancy, lymphadenopathy, or organomegaly.
3. ADAMTS13 Activity & Inhibitor Assay: Differentiate primary TTP from secondary MAHA.
4. Hemolysis Panel: Serum LDH, haptoglobin, reticulocyte count, and direct Coombs test.
5. Infectious Workup: Serum rK39 antigen (Kala-azar) and QuantiFERON-TB Gold.
Hello Attending Consultant here
Critique: Solid prioritization of secondary MAHA over primary TTP given B-symptoms, candidiasis, and smoking history. However, plan underweights urgent endoscopy/biopsy for dysphagia/early satiety and omits peripheral smear review + ADAMTS13 before further PLEX. Risk of catheter infection in elderly smoker not addressed.
Top 3 DDx:
1. Metastatic solid tumor (GI/lung) with marrow infiltration + paraneoplastic MAHA
2. Primary marrow process (MDS/AML)
3. Disseminated TB/fungal infection (endemic)
Specific points:
1. Hold PLEX pending ADAMTS13; schistocytes alone ≠ TTP.
2. Urgent EGD with biopsy (dysphagia + candidiasis may mask malignancy).
3. CT CAP + PET if mass found.
4. BM bx with cultures/cytogenetics immediately.
5. Quantiferon, fungal serologies, LDH/haptoglobin/retic.
6. Discontinue empiric PLEX if ADAMTS13 >10%.
7. Nutrition/supportive care; avoid further central access.
Hello, Expert Clinician here.
Senior Clinical Reasoning Expert: Best Current Unifying Diagnosis: Secondary thrombotic microangiopathy (MAHA) driven by an occult malignancy — most likely advanced esophageal/gastric adenocarcinoma or metastatic lung cancer with bone marrow infiltration.
Top Differentials:
1. Malignancy-associated MAHA + myelophthisis (Most likely): Fits perfectly — elderly smoker, 6kg weight loss, early satiety, solid-food dysphagia, B-symptoms, and candidiasis (a marker of immunosuppression/obstruction). Pancytopenia reflects marrow infiltration; schistocytes reflect tumor-associated microangiopathy.
2. Primary Marrow Failure (MDS/AML): Fits cytopenias and age, but does not explain the profound dysphagia, early satiety, and significant weight loss as elegantly.
3. Disseminated Infection (TB/Fungal/Visceral Leishmaniasis): Fits endemic exposure and fevers, but schistocytes and solid-food dysphagia are less typical.
4. Primary TTP (Least likely): The initial working diagnosis, but the subacute constitutional prodrome, B-symptoms, and dysphagia make a secondary trigger far more probable.
Key Pivot in the Case: The combination of solid-food dysphagia + early satiety + weight loss + candidiasis in an elderly smoker. This pivots the frame from a primary hematologic emergency (TTP) to a systemic malignancy with secondary hematologic consequences.
Most Important Next Diagnostic/Management Move: Urgent EGD with targeted biopsies (do not assume candidiasis is the sole pathology) and ADAMTS13 activity level before further PLEX. Hold plasma exchange if ADAMTS13 >10% and remove the tunneled line to mitigate infection risk.
Teaching Pearl: Not all schistocytes are TTP. In the elderly with B-symptoms and dysphagia, microangiopathy is often a paraneoplastic signal. Always hunt for the driver — treat the tumor, not just the smear.
Stage 2: Physical & Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C (afebrile), HR 72 bpm, BP 150/65 mmHg, RR 18/min, SpO2 97% on 2L NC. Pale conjunctivae, grade 2/6 systolic murmur at LSB, no petechiae, purpura, lymphadenopathy, or splenomegaly.
Initial Laboratory Evaluation:
- Pancytopenia: Hb 7.5 g/dL, Hematocrit 24.8%, WBC 2.74 x 10³/µL (neutrophils 21%, lymphocytes 72%, bands 6%), Platelets 43,000/µL. Reticulocyte count 3.0% (Reticulocyte Index 0.65%, hypoproliferative).
- Hemolytic & Microangiopathic Panel: Haptoglobin 113 mg/dL (NORMAL, not low), Total Bilirubin 0.7 mg/dL (normal), LDH 326 U/L (mildly elevated), Ferritin 564 µg/L, D-dimer 1166 ng/mL.
- ADAMTS13 Activity: 76% (Normal, ref ≥70%) — definitively ruling out TTP.
- Nutritional & Autoimmune: B12, Folate, Homocysteine, Copper, SPEP, Free Light Chains, DAT/IAT (Coombs), Dengue NS1, Leptspira Antibody,Malaria antigen, HIV, HBV, HCV all normal/negative.
Hello, Chief Resident here.
Updated Key Findings: Severe pancytopenia with a hypoproliferative reticulocyte index (0.65%), normal haptoglobin, and normal ADAMTS13 activity (76%), definitively ruling out TTP and active hemolysis.
Differential Diagnoses:
1. Solid Malignancy with Bone Marrow Myelophthisis (55%): Occult GI (esophageal/gastric) or pulmonary neoplasm unifies subacute constitutional symptoms, dysphagia, early satiety, immunosuppression, and non-hemolytic marrow failure.
2. Primary Hematologic Malignancy (MDS / AML) (25%): Highly plausible given advanced age, profound hypoproliferative cytopenias, and opportunistic fungal infection.
3. Disseminated Granulomatous Infection (TB / Deep Fungi) (15%): Endemic exposure, fevers, and marrow suppression; can present subacutely with constitutional decay.
4. Aplastic Anemia (5%): Explains hypoproliferative pancytopenia, though less unyielding of the GI prodrome and B-symptoms.
Prioritized Next Diagnostic & Management Steps:
1. Discontinue PLEX immediately and remove central access to mitigate infection risk.
2. Bone Marrow Aspirate & Biopsy: Flow cytometry, cytogenetics, and histopathology/cultures (AFB, fungal) to evaluate for myelophthisis versus primary dysplasia.
3. Urgent Upper GI Endoscopy (EGD): Targeted biopsy of esophageal/gastric mucosa to rule out occult carcinoma.
4. CT Chest, Abdomen, & Pelvis: Evaluate for primary GI/lung malignancy, lymphadenopathy, and occult metastases.
Hello Attending Consultant here
Critique: Correctly halts PLEX post-normal ADAMTS13 and prioritizes BM/EGD/CT. Underemphasizes smear morphology review and infectious marrow stains; omits nutrition optimization and smear for leucoerythroblastosis. Hypoproliferative indices + normal haptoglobin shift firmly from TMA to infiltrative/failure process.
Top 3 DDx:
1. Myelophthisic anemia from occult GI/lung adenocarcinoma
2. Primary MDS/AML with opportunistic candidiasis
3. Disseminated TB/fungal marrow infiltration
Specific points:
1. Immediate tunneled catheter removal.
2. Urgent BM bx: flow, cytogenetics, AFB/fungal stains/cultures.
3. EGD with biopsies (candidiasis may overlay carcinoma).
4. CT CAP ± PET for staging/occult primary.
5. Peripheral smear review for nucleated RBCs/teardrops.
6. Quantiferon + fungal serologies; hold empiric antimicrobials pending data.
7. Supportive transfusions/nutrition; avoid further lines.
Hello, Expert Clinician here.
Best unifying diagnosis: Marrow failure from occult malignancy — most concerning for upper GI adenocarcinoma (esophageal/gastric) with myelophthisis; metastatic lung cancer remains possible.
Why fits: Age/smoking, weight loss, early satiety, solid-food dysphagia, candidiasis, and hypoproliferative pancytopenia. Why not TTP: ADAMTS13 76%, normal haptoglobin/bilirubin, only mild LDH, and retic index 0.65 argue against active MAHA.
Top differentials:
1. Occult GI/lung malignancy with marrow infiltration — best explains systemic + GI symptoms.
2. MDS/AML — fits age, cytopenias, candidiasis; less explanatory for dysphagia/early satiety.
3. Disseminated TB/fungal infection — endemic, fevers, cytopenias; less specific for solid-food dysphagia.
4. Aplastic anemia — possible but less unifying.
Key pivot: Normal ADAMTS13 plus hypoproliferative indices reframes this from TTP to infiltrative marrow failure.
Next move: Urgent bone marrow aspirate/biopsy with flow, cytogenetics, AFB/fungal stains/cultures, plus EGD with biopsies and CT CAP. Stop PLEX/remove line.
Pearl: Schistocytes without hemolysis or ADAMTS13 deficiency should trigger a search for marrow invasion, not more plasma exchange.
Stage 3: Abdominopelvic Imaging & Smear Re-Evaluation (Timestamp: Hospital Days 1-3)
Diagnostic Workup:
- Abdomen/Pelvis CT: Bilateral adnexal soft-tissue masses (4.8 cm right with calcifications, 6.3 cm left). Normal spleen and liver. No pelvic or retroperitoneal lymphadenopathy. Tumor markers (CA-125, CA 19-9, CEA) normal.
- Peripheral Blood Smear Morphologic Re-Evaluation: Confirms anisopoikilocytosis, moderate schistocytes, giant platelets, hypogranular/hypolobated neutrophils (Pelger-Huët anomaly), and 1% circulating CD34+ myeloblasts without microangiopathic intravascular hemolysis features.
Hello, Chief Resident here.
Updated Key Findings: Bilateral adnexal masses (4.8 cm right, 6.3 cm left) with normal CA-125/CEA/CA19-9, alongside peripheral dysplastic features (Pelger-Huët anomaly, giant platelets, and 1% circulating CD34+ blasts) in an elderly female with hypoproliferative pancytopenia and GI symptoms.
Differential Diagnoses:
1. Primary MDS / AML (50%): Pelger-Huët neutrophils, giant platelets, and circulating blasts strongly favor primary myelodysplasia/leukemia. Adnexal lesions may represent extramedullary myeloid tumors (granulocytic sarcoma) or coexisting pathology.
2. Gastric Adenocarcinoma with Krukenberg Tumors & Myelophthisis (35%): Solid-food dysphagia, early satiety, and bilateral adnexal masses classic for primary upper GI malignancy metastasizing to ovaries and bone marrow.
3. Disseminated Granulomatous Infection (TB / Deep Fungi) (10%): Can present with bilateral adnexal/tubo-ovarian masses, B-symptoms, and marrow suppression in endemic regions.
4. Primary Epithelial Ovarian Malignancy (5%): Less likely given normal tumor markers and dysplastic smear features, but remains possible.
Prioritized Next Diagnostic Steps:
1. Bone Marrow Aspirate & Biopsy: Cytogenetics, flow cytometry, NGS panel for MDS/AML, and AFB/fungal cultures.
2. Urgent Upper GI Endoscopy (EGD): Biopsy gastric/esophageal mucosa to detect primary Krukenberg source.
3. Pelvic MRI: Further characterize adnexal tissue architecture.
4.
Hello Attending Consultant here
Critique: Appropriately elevates MDS/AML given Pelger-Huët, giant platelets, and circulating blasts; correctly retains Krukenberg in DDx. Plan incomplete—omits chest imaging, full cytogenetic/NGS urgency, and risks delaying EGD while pursuing MRI. Normal markers do not exclude mucinous GI primary.
Top 3 DDx:
1. Primary MDS/AML (± myeloid sarcoma of adnexa)
2. Gastric adenocarcinoma (Krukenberg) + myelophthisis
3. Metastatic lung ca (smoker) with ovarian/marrow deposits
Specific points:
1. Urgent BM aspirate/biopsy + flow/cytogenetics/NGS (MDS panel) + cultures.
2. Immediate EGD + biopsies (dysphagia + possible Krukenberg source).
3. Add CT chest; consider PET if primary occult.
4. Pelvic MRI only after BM/EGD; Gyn-onc consult for masses.
5. Peripheral flow to quantify blasts; smear for dysplasia scoring.
6. Supportive care; no empiric chemo pending lineage confirmation.
7. Remove any residual central access.
Hello, Expert Clinician here.
Best unifying diagnosis: Primary myelodysplastic syndrome (MDS) with excess blasts / evolving AML, with bilateral adnexal myeloid sarcoma (granulocytic sarcoma) as the likely explanation for the pelvic masses.
Why fits: Pelger-Huët anomaly, giant platelets, hypogranular neutrophils, and 1% circulating CD34+ blasts are classic dysplastic features. Myeloid sarcoma can present as isolated adnexal masses with normal tumor markers, preceding or accompanying marrow disease.
Top differentials:
1. MDS/AML with myeloid sarcoma (Most likely): Unifies cytopenias, dysplasia, blasts, and adnexal lesions.
2. Gastric adenocarcinoma with Krukenberg tumors + myelophthisis: Fits dysphagia/early satiety and bilateral adnexal masses, but does not explain Pelger-Huët or circulating blasts.
3. Disseminated TB/fungal infection: Can cause adnexal masses and marrow suppression, but dysplastic smear features argue against.
Key pivot: The peripheral smear re-evaluation — Pelger-Huët + giant platelets + circulating blasts — shifts the frame from metastatic solid tumor to primary myeloid neoplasm with extramedullary disease.
Next move: Urgent bone marrow aspirate/biopsy with flow cytometry, cytogenetics, and NGS; biopsy of adnexal mass (image-guided or laparoscopic) to confirm myeloid sarcoma; EGD to exclude coexisting gastric primary.
Pearl: Myeloid sarcoma can precede marrow involvement by months. Bilateral adnexal masses with normal CA-125 in a cytopenic elderly patient should prompt biopsy — chloromas mimic ovarian cancer but demand entirely different therapy.
Stage 4: Bone Marrow Aspirate, Biopsy & Cytogenetics (Timestamp: Hospital Days 3-5)
Bone Marrow Biopsy & Cytogenetics:
- Morphology: Hypercellular marrow (50–60%) with left-shifted myeloid maturation, marked multilineage dysplasia (small hypolobated megakaryocytes and hyperchromatic forms), and 10% CD34+ CD117+ myeloblasts (flow cytometry CD13+ CD33+ MPO+ CD34+ CD117+ HLA-DR+).
- Cytogenetics & FISH: Complex karyotype showing Trisomy 8, Monosomy 5, and 5q deletion in 65% of metaphases.
- Next-Generation Sequencing (NGS): High-risk driver mutations in DNMT3A (p.Arg882Cys, VAF 36.8%) and TP53 (p.Val216Met, VAF 16.0% and p.Val143Met, VAF 29.4%).
- Pathology Unifying Diagnosis: Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2).
Hello, Chief Resident here.
Updated Key Findings: Bone marrow biopsy confirms Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2) with 10% blasts, multilineage dysplasia, complex cytogenetics (Trisomy 8, Monosomy 5, 5q-), and high-risk TP53 and DNMT3A mutations.
Differential Diagnoses:
1. Primary MDS-EB2 with Extramedullary Myeloid Sarcoma of Adnexa (85%): Definitive marrow pathology confirms MDS-EB2. Bilateral adnexal masses in this context represent extramedullary manifestation (chloroma/granulocytic sarcoma).
2. Coexisting Primary Gastric Adenocarcinoma with Krukenberg Tumors (10%): High-risk MDS confirmed, but persistent dysphagia and early satiety raise concern for a synchronous primary GI neoplasm.
3. Disseminated Granulomatous Infection in High-Risk MDS (5%): Opportunistic tubo-ovarian infection secondary to profound dysplastic neutropenia.
Prioritized Next Diagnostic & Management Steps:
1. Targeted Image-Guided Biopsy of Adnexal Mass: Immunohistochemistry (MPO, CD34, CD117) to prove extramedullary myeloid sarcoma versus epithelial malignancy.
2. Urgent EGD: Biopsy esophageal/gastric mucosa to evaluate persistent dysphagia and exclude synchronous primary GI malignancy.
3. Initiate Hypomethylating Agent (HMA) Therapy: Azacitidine ± Venetoclax following diagnostic confirmation.
4. Gyn-Oncology & Hematology Consultations: Multidisciplinary planning for extramedullary myeloid disease.
5. Supportive Care: Transfusion thresholds, antifungal prophylaxis.
Hello Attending Consultant here
Critique: Accurately pins primary diagnosis to MDS-EB2; soundly links adnexal masses to myeloid sarcoma vs synchronous Krukenberg. Plan effectively targets mass biopsy and EGD. Needs clearer risk-stratification (IPSS-M) to frame HMA strategy and explicit warning on Venetoclax toxicity in multi-mutated/elderly patients.
Top 3 DDx:
1. MDS-EB2 with adnexal myeloid sarcoma (chloroma)
2. Synchronous gastric adenocarcinoma (Krukenberg) + MDS-EB2
3. MDS-EB2 with benign/infectious adnexal pathology
Specific points:
1. Immediate core biopsy of adnexal mass: IHC for MPO, CD34, CD117, lysozyme.
2. EGD with biopsies (must resolve upper GI symptoms).
3. IPSS-M score calculation (very high risk: complex, -5, TP53, DNMT3A).
4. Start Azacitidine; hold Venetoclax pending performance status/organ function and infection risk.
5. Infection prophylaxis (mold-active antifungal, fluoroquinolone, acyclovir).
6. Gyn-oncology consult for symptom control/possible surgical intervention if mass effect/torsion.
7. Palliative/goals-of-care discussion given poor prognosis (TP53 + complex karyotype).
Definitive Primary Diagnosis: High-Risk Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2) (Complex karyotype with -5/5q-, TP53 and DNMT3A mutations).
Unified Clinical Picture: The subacute B-symptoms, cytopenias, candidiasis, and pseudomicroangiopathy were secondary to primary marrow failure from high-risk MDS. The bilateral adnexal masses represent extramedullary myeloid sarcoma (granulocytic sarcoma) — a recognized, aggressive manifestation of high-risk MDS/AML.
Top Differential for Adnexal Masses:
1. Extramedullary Myeloid Sarcoma (85%): Driven by high-risk cytogenetics and TP53 mutation; fits presentation with blasts/dysplasia.
2. Synchronous Gastric Adenocarcinoma with Krukenberg Tumors (10%): Explains dysphagia/early satiety, but secondary to MDS.
3. Atypical Tubo-ovarian Infection (5%): Secondary to neutropenia.
Key Pivot: Identification of 10% blasts, multilineage dysplasia, -5/5q-, and TP53 mutations seals MDS-EB2 and strongly implicates myeloid sarcoma as the cause of the adnexal tumors.
Next Diagnostic & Management Steps:
1. Core Biopsy of Adnexal Mass: Confirm myeloid sarcoma (MPO, CD34, CD117, CD68).
2. EGD: Evaluate dysphagia/early satiety to rule out synchronous GI lesion.
3. Therapy: Hypomethylating agent (Azacitidine); calculate IPSS-M (Very High Risk).
4. Supportive Care: Antimicrobial prophylaxis, transfusions, and early goals-of-care discussion given poor median survival with TP53-mutated MDS.
Teaching Pearl: Extramedullary myeloid sarcoma can present as pelvic masses mimicking ovarian cancer. In high-risk MDS, always tissue-diagnose new soft-tissue masses before assuming a second primary.
Hello Attending Consultant here
Critique: Correctly locks MDS-EB2 as primary diagnosis and prioritizes adnexal biopsy + EGD. Over-eager on immediate Venetoclax (high toxicity in elderly TP53-mutated disease); under-specifies IPSS-M/IPSS-R scoring and infection prophylaxis intensity. Goals-of-care discussion delayed.
Top 3 DDx:
1. MDS-EB2 + adnexal myeloid sarcoma
2. MDS-EB2 + synchronous Krukenberg (gastric primary)
3. MDS-EB2 + infectious adnexal mass
Specific points:
1. Image-guided adnexal core bx: IHC MPO/CD117/CD34/lysozyme stat.
2. EGD + biopsy to close dysphagia workup.
3. Calculate IPSS-M (very high-risk: complex karyotype, -5/5q-, biallelic TP53).
4. Start azacitidine monotherapy; defer venetoclax pending PS/infection clearance.
5. Mold-active antifungal + antibacterial prophylaxis.
6. Gyn-onc + palliative care co-management.
7. Transfuse judiciously; no further central lines.
Hello, Expert Clinician here.
Best unifying diagnosis: High-risk MDS-EB2 (complex karyotype, biallelic TP53, DNMT3A) with extramedullary myeloid sarcoma of bilateral adnexa.
Why fits: 10% blasts, multilineage dysplasia, -5/5q-, and TP53 mutations define MDS-EB2. Adnexal masses with normal CA-125 in this context are classic chloromas. Dysphagia/candidiasis reflect neutropenic immunosuppression.
Top differentials:
1. MDS-EB2 + myeloid sarcoma (Most likely): Unifies marrow failure, dysplasia, blasts, and adnexal masses.
2. Synchronous gastric adenocarcinoma (Krukenberg): Explains dysphagia/early satiety but not dysplasia/blasts; must exclude via EGD.
3. Infectious adnexal mass: Possible in neutropenia but less likely given bilateral solid appearance.
Key pivot: Marrow morphology + cytogenetics/NGS — 10% blasts, -5/5q-, TP53 — seals MDS-EB2 and reframes adnexal masses as extramedullary disease.
Next move: Image-guided adnexal core biopsy (MPO/CD117/CD34) to confirm myeloid sarcoma; EGD to exclude synchronous gastric primary; calculate IPSS-M; initiate azacitidine; early palliative care given dismal TP53-mutated prognosis.
Pearl: TP53-mutated MDS with complex karyotype behaves like AML — treat aggressively but anchor goals-of-care early; extramedullary disease signals systemic relapse risk.
Stage 5: Targeted Hypomethylating Therapy & Clinical Course (Timestamp: Follow-up & Discharge)
Management & Outcome:
- Management Decision: Discontinuation of PLEX. High-risk IPSS-R score (7.5). Initiated on Azacitidine (75 mg/m² IV daily x 7 days every 28 days).
- Clinical Outcome:
- Achieved temporary hematologic response after 3 cycles (resolution of neutropenia and transfusion independence for 6 months).
- Disease progression to 15% blasts at 6 months. Succumbed to acute exacerbation of heart failure and neutropenic fever 9 months after diagnosis.
Hello, Chief Resident here.
Final Key Findings: High-risk MDS-EB2 (IPSS-R 7.5, TP53, complex karyotype) initially achieved a 6-month hematologic response to Azacitidine, followed by leukemic progression (15% blasts) and death from neutropenic fever and acute heart failure at 9 months.
Final Probability-Based Diagnoses:
1. High-Risk MDS-EB2 with Extramedullary Progression (85%): Primary driver of initial presentation (pseudo-TTP/myelophthisis), adnexal involvement, and eventual disease relapse.
2. Neutropenic Sepsis (10%): Primary immediate terminal cause secondary to severe disease progression and marrow failure.
3. Acute Decompensated Heart Failure (5%): Contributory terminal event triggered by septic and metabolic stress.
Clinical Takeaways & Recommendations:
1. Avoid PLEX Anchor Bias: Normal ADAMTS13 (76%) and hypoproliferative indices successfully redirected management away from TTP toward primary marrow pathology.
2. Recognize High-Risk Cytogenetics: TP53 mutations and complex karyotype predict short-lived responses to hypomethylating agents, underscoring the aggressive natural history of MDS-EB2.
3. Multidisciplinary Management: Early integration of palliative care alongside active HMA therapy is critical in TP53-mutated myeloid neoplasms to align treatment goals with prognosis.
Hello Attending Consultant here
Critique: Accurate closure on MDS-EB2 natural history and HMA limitations. Overstates "extramedullary progression" without confirmatory adnexal histology; under-emphasizes missed early goals-of-care and cardiac risk stratification in elderly smoker. Terminal events correctly linked to progressive marrow failure.
Top 3 DDx (final):
1. High-risk MDS-EB2 (TP53/complex) ± myeloid sarcoma
2. MDS-EB2 with synchronous occult solid tumor
3. Therapy-related complications (neutropenic sepsis + HF)
Specific points:
1. Confirm adnexal histology retrospectively if tissue available.
2. IPSS-M re-scoring at progression; consider clinical trial/allo-HCT eligibility earlier.
3. Mandatory early palliative integration for TP53-mutated disease.
4. Baseline echo/cardiology co-management given smoking/HTN and HF terminal event.
5. Mold-active prophylaxis duration through all cycles.
6. Document ADAMTS13-driven PLEX cessation as key diagnostic pivot.
7. Autopsy consideration for definitive extramedullary status.
Hello, Expert Clinician here.
Final unifying diagnosis: High-risk MDS-EB2 (IPSS-R 7.5, complex karyotype, biallelic TP53, DNMT3A) with probable extramedullary myeloid sarcoma of adnexa; terminal events were neutropenic sepsis and acute heart failure from progressive marrow failure.
Why fits: Dysplasia, 10% blasts, -5/5q-, and TP53 mutations define MDS-EB2. Transient HMA response followed by progression at 6 months is classic for TP53-mutated disease. Adnexal masses likely chloromas; dysphagia/candidiasis reflected neutropenia.
Top differentials:
1. MDS-EB2 ± myeloid sarcoma (Most likely): Unifies all findings.
2. Synchronous gastric adenocarcinoma: Never excluded by EGD; remains possible contributor to dysphagia.
3. Therapy-related complications: Sepsis/HF were terminal, not primary.
Key pivot: Normal ADAMTS13 + hypoproliferative indices redirected from TTP to marrow pathology; cytogenetics/NGS sealed high-risk biology.
Most important move (retrospective): Earlier goals-of-care discussion and consideration of allo-HCT/clinical trial at diagnosis given dismal TP53 prognosis.
Pearl: TP53-mutated MDS is a "bad actor" — HMA responses are brief; anchor prognosis early and prioritize quality of life alongside disease-directed therapy.